Never miss out on the latest news!
Over 4,000 healthcare professionals have already signed up.
Boosting confidence in preventing recurrent thrombotic events in patients with peripheral artery disease following revascularization
For Jim*, peripheral revascularization helped to ease claudication stemming from peripheral artery disease (PAD). However, this was his second revascularization procedure, and Jim fears that he may need another, or even face amputation in the future.
Is there anything that can be done to protect Jim from these feared consequences of PAD?
*Fictional patient
Patients with PAD remain at high thrombotic risk after revascularization
Even after revascularization, patients with PAD remain at high risk of cardiovascular and limb events , with the risk rising from approximately 1 in 6 patients after 1 year to approximately 1 in 3 patients after 4.5 years.1 For patients who experience major adverse limb events (MALE) after revascularization, the consequences are especially concerning, because these patients are approximately 8 times more likely to need another revascularization or a limb amputation, highlighting the need to prevent post-revascularization MALE.2
To reduce the risk of cardiovascular and limb events after revascularization, patients are often prescribed intensified antithrombotic therapy, such as dual antiplatelet therapy (DAPT). 3,4 However, the guideline recommendations are largely extrapolated from data in the coronary revascularization setting, and evidence on the benefit of intensified antithrombotic therapy after peripheral revascularization is scarce.3,5-7 Previous trials in patients with symptomatic PAD following peripheral revascularization treated with either a vitamin K antagonist or DAPT showed no clinical benefit in graft occlusion, revascularization, above-ankle amputation, death or severe bleeding compared with antiplatelet therapy alone.8,9 However, adjudicated major bleeding complications were increased in those treated with a vitamin K antagonist compared with aspirin.9 These findings highlighted the need for adequately powered randomized trials of antithrombotic treatment in a primary PAD population following revascularization with adjudicated major adverse cardiovascular events, MALE and bleeding endpoints.3
After revascularization, patients with PAD need protection from repeat events and hospitalization
The first trial to demonstrate significant protection from major adverse vascular events in patients with PAD following recent revascularization was VOYAGER PAD (N=6564).10 In this trial, dual pathway inhibition (DPI) with rivaroxaban vascular dose 2.5 mg twice daily (bid) plus aspirin 100 mg once daily (od) versus aspirin 100 mg od showed a 15% reduction (HR 0.85; 95% CI 0.76–0.96; p=0.009) in the composite primary efficacy endpoint of acute limb ischaemia, major amputation of vascular aetiology, myocardial infarction, ischaemic stroke or cardiovascular death.10 Furthermore, the primary safety outcome of TIMI (Thrombolysis In Myocardial Infarction) major bleeding was not significantly different with DPI versus aspirin (HR 1.43; 95% CI 0.97–2.10; p=0.07).10 These results suggest protection with DPI against thrombotic events in multiple vascular beds, with manageable bleeding events.
Reassuringly, there were also reductions in secondary limb outcomes with DPI versus aspirin, including a 12% reduction in unplanned revascularization of the index leg for recurrent ischaemia (hazard ratio [HR]=0.88; 95% confidence interval [CI] 0.79–0.99; p=0.03).10 Furthermore, hospitalization for coronary or peripheral event of a thrombotic nature was reduced by 28% (HR=0.72; 95% CI 0.62–0.85; p<0.001) with DPI compared with aspirin.10 Therefore, DPI shows promise not only in reducing major adverse vascular events, but also in protecting patients from the burden of repeat procedures and return to hospital.
DPI reduced the risks of repeat revascularization and hospitalization10
bid, twice daily; CI, confidence interval; DPI, dual pathway inhibition; HR, hazard ratio; od, once daily
As vascular surgeon Professor Sebastian Debus explains in this video, ‘[Rivaroxaban 2.5 mg bid plus aspirin 100 mg od] now has a severe benefit for all our PAD patients since the risk of redo surgery, rehospitalization, reduced overall lifetime and the risk of acute limb events and cardiac events is markedly reduced.’
Protection from thrombotic events with DPI in the post-revascularization setting is now reflected in the rivaroxaban label
The results of VOYAGER PAD led to specific recommendation updates to the European label of rivaroxaban 2.5 mg bid plus low-dose aspirin for the prevention of atherothrombotic events in patients with symptomatic PAD at high risk of ischaemic events, including those with a recent lower-extremity revascularization.11
Recent European label update builds confidence in DPI for patients with symptomatic PAD at high risk of ischemic events following a recent lower-extremity revascularization11
DAPT, dual antiplatelet therapy; DPI, dual pathway inhibition; PAD, peripheral artery disease; TIA, transient ischaemic attack
The updated European label adds to the recommendations from the 2019 European Society of Vascular Medicine (ESVM) guidelines, the 2019 Global Vascular Guidelines (GVG) and the 2019 European Society of Cardiology (ESC) guidelines on PAD that DPI with rivaroxaban 2.5 mg bid plus low-dose aspirin should be considered in all patients with symptomatic PAD without high risk of bleeding or other contraindications.5-7 The guideline recommendations are based on the results of the COMPASS trial, which investigated DPI in patients with chronic coronary artery disease and/or PAD.12-14 The approval by regulatory authorities and the clinical guidelines build confidence in protecting patients with PAD from major adverse vascular events both in the short- and long-term. As vascular physician Professor Rupert Bauersachs summarizes in this video, ‘Dual pathway inhibition provides a simple and effective management to the vascular physician, of course, to the patient also, covering the immediate and long-term phase, starting right after the revascularization and continuing long term.’
Looking forward
The broadening of the European label for rivaroxaban provides guidance on the use of DPI in patients with symptomatic PAD following peripheral revascularization, and provides reassurance that you have an effective treatment option to reduce the risk of major adverse vascular events, including repeat revascularizations and hospitalizations, in patients like Jim.
References
- Desai U, Kharat A, Hess CN et al. Incidence of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization. Ann Vasc Surg 2021;75:217–226. Return to content
- Hess CN, Wang TY, Weleski Fu J et al. Long-term outcomes and associations with major adverse limb events after peripheral artery revascularization. J Am Coll Cardiol 2020;75:498–508. Return to content
- Hess CN, Norgren L, Ansel GM et al. A structured review of antithrombotic therapy in peripheral artery disease with a focus on revascularization: a TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) initiative. Circulation 2017;135:2534–2555. Return to content
- Jones WS, Mi X, Qualls LG et al. Significant variation in P2Y12 inhibitor use after peripheral vascular intervention in Medicare beneficiaries. Am Heart J 2016;179:10–18. Return to content
- Frank U, Nikola S, Belch J. European Society for Vascular Medicine (ESVM). Guideline on peripheral arterial disease. Vasa 2019;48:1–12. Return to content
- Aboyans V, Ricco JB, Bartelink MEL et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Rev Esp Cardiol (Engl Ed) 2018;71:111. Return to content
- Conte MS, Bradbury AW, Kolh P et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 2019;58:S1–S109 e133. Return to content
- Belch JJ, Dormandy J, CASPAR Writing Committee. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010;52:825–833. Return to content
- Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 2000;355:346–351. Return to content
- Bonaca MP, Bauersachs RM, Anand SS et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020;382:1994–2004. Return to content
- Bayer AG. Xarelto (rivaroxaban) Summary of Product Characteristics. 2021. Available at: https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf [accessed 28 Oct 2021]. Bayer AG. Xarelto (rivaroxaban) Summary of Product Characteristics. 2021. Available at: https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf [accessed 28 Oct 2021]. Return to content
- Eikelboom JW, Connolly SJ, Bosch J et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377:1319–1330. Return to content
- Fox K. European Society of Cardiology chronic coronary syndromes guidelines review. EMJ Cardiol 2019;7:38-45. Return to content
- Knuuti J, Wijns W, Saraste A et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407–477. Return to content
See Also
When should dual pathway inhibition be stopped in patients with symptomatic PAD following peripheral revascularization?
See Also
Can the risk of vascular events be reduced in patients with peripheral artery disease undergoing lower-extremity endovascular revascularization?
See Also
Patients with chronic PAD – What can be done to reduce the risk of cardiovascular and limb events?
Copyright © Bayer AG |
- PP-XAR-ALL-2418-1
Updated date 10/10/2022
This website is intended to provide information to an
international audience outside the USA and UK.
